ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1073

Results of a Phase 2 RCT of ALLN-177 in Patients with Secondary Hyperoxaluria

Session Information

Category: Mineral Disease

  • 1204 Mineral Disease: Nephrolithiasis


  • Nigwekar, Sagar U., Massachusetts General Hospital , Boston, Massachusetts, United States
  • Lingeman, James E., IU Health Physicians Urology, Indianapolis, Indiana, United States
  • Bolognese, James A, Cytel inc, Cambridge, Massachusetts, United States
  • Kausz, Annamaria T., Allena Pharmaceuticals, Newton, Massachusetts, United States

Hyperoxaluria (HOx) is a metabolic disorder associated with increased risk of nephrolithiasis and other sequelae including oxalate nephropathy. Secondary HOx is caused by excess oxalate absorption from diet due to enteric disorders (enteric HOx, EH) or is unexplained (idiopathic). There are no approved pharmacotherapies for HOx. To address this unmet need, ALLN-177 was developed as a novel oral formulation of crystalline oxalate decarboxylase, an oxalate-specific enzyme that degrades oxalate in the gastrointestinal (GI) tract, thereby reducing urine oxalate (UOx).


This double-blind, placebo-controlled RCT randomized adult subjects with secondary HOx and UOx ≥50 mg/d 1:1 to ALLN-177 (7500 u/meal) or placebo taken orally with meals 3x/day for 28 days. Multiple 24-hr urine collections were obtained to determine change in UOx, and the primary analysis used a mixed effects repeated measures analysis of variance model.


67 subjects were randomized and treated (32 ALLN-177, 35 placebo); 18 had EH. The primary endpoint (EP) 24-hr UOx change from baseline to Week (Wk) 4 showed a trend favoring ALLN-177 (-5.4 mg/d; see Table). Key secondary EP were statistically significant, and a substantially greater, clinically meaningful treatment effect was seen in post-hoc analyses in the predefined EH subset, including the time-weighted average (TWA) assessing the aggregate effect across the study duration.
Adverse events were reported by 50% of ALLN-177 subjects vs. 63% placebo, and GI AEs were the most frequently reported, 16% ALLN-177 vs 40% placebo. No subjects discontinued ALLN-177 for any reason.


ALLN-177 was well-tolerated and has potential to meaningfully reduce UOx in patients with EH, who have a substantially increased risk for renal complications and thus an unmet need for an effective therapy to reduce UOx.

 Comparison vs. Placebo
mean (90% CI)
Comparison vs. Placebo
mean (90% CI)
Least squares mean change in UOx to Wk4 – mg/d-5.4 (-14.05, 3.16)-15.4 (-46.31, 15.62)
Change in TWA UOx (Wks1-4) – mg/d-6.7 (-13.03, -0.30)-23.1 (-43.95, -2.15)
% change in UOx to Wk4-13.18% (-24.66, -1.71)-35.3% (-70.19, -0.41)


  • Commercial Support